首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Note: Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Doses
【2h】

Note: Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Doses

机译:注意:多次标准临床剂量后哌拉西林和他唑巴坦表现出线性药代动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A population pharmacokinetic (PK) analysis was conducted to determine if piperacillin and tazobactam exhibited linear or nonlinear PKs and if incremental changes in the daily dosage of piperacillin affected tazobactam PKs. Four dosage groups were evaluated after multiple dosing regimens. Concentrations of drug in plasma and amounts in urine were best fitted by using a linear two-compartment PK model. No significant difference between dosing groups was seen for any piperacillin or tazobactam PK parameters. Both drugs exhibited linear PKs when given at usual clinical doses. Tazobactam PKs did not appear to be affected by the different dosing regimens of piperacillin.
机译:进行了群体药代动力学(PK)分析,以确定哌拉西林和他唑巴坦是否表现出线性或非线性PK,以及哌拉西林每日剂量的增量变化是否影响他唑巴坦PK。在多次给药方案后评估了四个剂量组。血浆中的药物浓度和尿液中的浓度最好通过使用线性二室PK模型拟合。对于任何哌拉西林或他唑巴坦PK参数,给药组之间均无显着差异。当以常规临床剂量给予时,两种药物均表现出线性PK。他唑巴坦PKs似乎不受哌拉西林不同给药方案的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号